SillaJen IPO Part 2 - Growth Potential & Appropriate Valuation Level
* In Part 2 (as below), I summarized the growth potential and appropriate valuation level of SillaJen.Apparently, not many people are doubtful...
261 Views
The Chickens Are Ready to Roost
Several recent developments confirm our thesis that Inflectra's US sales in 2017 will fall far short of management's 2017 forecast. First, Pfizer's...
202 Views
Teva May Buy Celltrion - Implications for Celltrion & Celltrion Healthcare
How should we interpret Teva's potential acquisition of Celltrion? Is this for real? Well, Teva may still be very interested in acquiring Celltrion...
209 Views
More Harsh Reality from Teva
U.S. healthcare industry leaders from across the spectrum of industry segments continue to downplay the near-term adoption of biosimilars in the...
198 Views
Celltrion Healthcare IPO, Unlikely to Have Owner Premium Factor
Celltrion Healthcare, Celltrion (068270)’s overseas sales and marketing unit, decided to be listed in KOSDAQ (instead of Korea’s main bourse) as...
329 Views